Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.
Neurocrine Biosciences Inc. and Voyager Therapeutics Inc. are joining forces to develop gene therapies for Parkinson's and Friedreich's ataxia, and two other programs in the future, in a high-value deal around central nervous system (CNS) assets analysts see as a good fit for both parties.
The collaboration was announced Jan. 29. Neurocrine will pay Voyager $165m upfront ($115m in cash and $50m in equity investment), plus funding for clinical development, and up to $1
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
An ‘historic economic prosperity deal’ does not include the sector.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
